Komori
Eisai (4523) · InitiativeFirst stated

Personalized Medicine Using Circulating Tumor DNA and Next-Generation Sequencing

First written in FY2021. . Latest entry: FY2021.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Advancing Personalized Healthcare and Cancer Genomic MedicineA theme 4 companies write about · 0 as a headwind · 10 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2021First statedAnnual report

    「オンコロジー領域では、継続的な血中の循環腫瘍DNA解析と次世代シーケンス解析によりがんの進化を深く理解し、ゲノム情報に基づく早期診断、患者様ごとに最適な治療法の選択が可能となる個別化医療の実現をめざします。」

    がん領域で、循環腫瘍DNAと次世代シーケンスを用いた早期診断・個別化医療の実現手段を初めて独立したテーマとして示した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Personalized Medicine Using Circulating Tumor DNA and Next-Generation Sequencing | Eisai Co.,Ltd. (4523) | Komori